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Objective: To describe the insights on the epidemiology of pain-structure association and the ramiﬁcations
of these studies for clinical trials.
Design: Narrative review summarizing the pertinent literature in this area, summarizing some of the
methodologic challenges inherent and proposing some research initiatives to further understanding of
this complex science.
Results: The predominant symptom in most patients presenting with osteoarthritis (OA) is pain. Over
recent years a number of imaging based studies have narrowed the discord between structural ﬁndings
on imaging and symptoms. The interpretation of pain in OA is still enigmatic and difﬁcult to deal with
both for clinicians and scientists.
Conclusions: We would envisage that over the next few years many of the pressing questions pertaining
to research into the structure pain relationship will continue to be addressed. With this, we can expect
clinically appropriate therapeutic advance.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a highly prevalent and disabling disease
that consequently has a formidable individual and societal impact.
Approximately 10e12% of the adult population have symptomatic
OA1,2. The risk of mobility disability (deﬁned as needing help
walking or climbing stairs) attributable to knee OA alone is greater
than that due to any other medical condition in people aged 65 and
over3,4. Recent estimates suggest that 250 million people world-
wide are burdened by the presence of knee OA5.
This prevalent and disabling disease is heterogeneous and
characterized by failure of the synovial joint organ6. The disease
occurs when the dynamic equilibrium between the breakdown and
repair of joint tissues becomes unbalanced, often in a situation
where the mechanical loads applied exceed those that can be
tolerated by the joint tissues7. OA is a heterogeneous disease that is
characterized by progressive cartilage loss, subchondral bone
remodelling, osteophyte formation, and synovial inﬂammation,
with resultant joint pain and increasing disability. Whilst theD.J. Hunter, Kolling Institute,
1887; Fax: 61-294631077.
Hunter).
s Research Society International. Pprogressive joint failure may cause pain and disability4 approxi-
mately 50% of persons with structural changes consistent with OA
are asymptomatic8.
In epidemiological investigation, OA is typically deﬁned using
conventional radiographs, and less frequently self-report9. The re-
ported prevalence of OA varies according to the method used to
deﬁne the disease. The characteristic radiographic features used to
deﬁne and classify OA severity are osteophytes (osteocartilaginous
growths), subchondral sclerosis and joint space narrowing. Symp-
tomatic OA in contrast requires the concomitant presence of pain
(usually deﬁned as pain on most days of the last month) and
radiographic features. It is the presence of symptomatic OA that is
important clinically, not simply the radiographic identiﬁcation of
an osteophyte or self-reported OA (where misclassiﬁcation is even
more problematic than the commonly used radiographic OA
deﬁnition).
The predominant symptom inmost patients presenting with OA
is pain. Over recent years a number of imaging based studies have
narrowed the discord between structural ﬁndings on imaging and
symptoms10,11. This narrative review will summarize these ﬁndings
and provide insights to the epidemiology of the pain-structure
association and the ramiﬁcations of these studies for clinical trials
especially pertaining to structure modiﬁcation. We present here a
narrative review, supported by a literature search up to Januaryublished by Elsevier Ltd. All rights reserved.
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tematic review and prior reviews were referenced for their content.
The determinants of pain
The determinants of pain in OA are not well understood, but are
believed to involve multiple interactive pathways that are best
framed in a biopsychosocial framework (posits that biological,
psychological and social factors all play a signiﬁcant role in pain in
OA)12,13 (Fig. 1). Psychosocial factors that can predispose to symp-
toms include self-efﬁcacy and pain catastrophizing, and the social
context of arthritis (social support, pain communication) are all
important considerations in understanding the pain experience.
From a biological perspective, neuronal activity in nociceptive
pathways is responsible for the generation of signals that ulti-
mately are interpreted as joint pain. During inﬂammation or tissue
(joint) injury, mediators are released into the joint that sensitize
primary afferent nerves such that normally innocuous joint
movements (such as increased physical activity, walking on high
heeled shoes) may elicit a painful response. This is the neuro-
physiological basis of allodynia, i.e., the sensation of pain in
response to a normally non-painful stimulus such as walking14.
Over time, this increased neuronal activity from the periphery
(peripheral sensitization) can contribute to plasticity changes in the
central nervous system (central sensitization)15. In this instance,
second order neurons in the spinal cord becomemore responsive to
peripheral input, such as responding to lower-threshold stimuli
that would not normally cause the neurons to ﬁre, or an expansion
of the receptive ﬁeld of the dorsal horn neurons such that the
transmission of nociceptive information to the somatosensory
cortex is enhanced. Central sensitization can intensify the sensationFig. 1. Biospsychosocial model depicting the relation oof pain and even lead to pain responses from regions of the body
remote from the inﬂamed joint, i.e., referred pain14.
Another important component of the biological contribution to
pain comes from the multitude of tissues within the joint that
contain nociceptive ﬁbres and these are the likely sources of pain in
OA. The subchondral bone, periosteum, peri-articular ligaments,
periarticular muscle and joint capsule including its inner synovial
lining are all richly innervated and are the likely source of noci-
ception in OA. However, subjects with the same degree of structural
damage experience widely different levels of pain, a phenomenon
that is poorly understood13.
Research into pain is challenging as a result of the multiple risk
factors responsible for pain occurrence and pain severity as well as
pain being a subjective phenomenon. In population studies there is
a signiﬁcant discordance between radiographically diagnosed OA
and knee pain8. Whilst radiographic evidence of joint damage pre-
disposes to joint pain, the underlying pathologies leading to pain
cannot be readily discerned from radiography alone and may
require consideration of other factors including function and load16.
Novel study designs are one approach to deal with the so-called
structure-symptom discordance. For example, when inter-
individual differences inﬂuencing the pain experience (e.g., ge-
netics, psychosocial factors, etc.) are adequately accounted for, a
strong relationship between radiographic OA and knee pain has
been noted17. In addition, it is important to consider that structural
pathology is associated with somatosensory deﬁcits in OA, since the
extent of sensory loss directly correlated with the radiographic
severity of knee OA, although causality has not been discerned18.
One study applying direct unanesthetized examination of articular
tissues in the human knee joint has provided some insight into
particular structures that do and do not elicit painwhenprobed19. Inf structural pathology to the experience of pain.
Table I
OA structure pain correlation studies
Structural feature Number of supportive studies (references)
Supportive of
association
Negative or neutral
ﬁndings
Bone marrow lesions 521,26e29 230,31
Synovitis 321,22,32 223,33
Effusion 322,26,31
Cartilage 328,30,34 131
Meniscus 121 430,31,35,36
Bone attrition 121
Osteophytes 131 121
Peri-articular lesions 137 131
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such as magnetic resonance imaging (MRI), numerous structural
alterations evident on MRI such as subchondral bone marrow le-
sions20, subarticular bone attrition21, synovitis and effusion22,23
have been related to knee pain. Furthermore, changes in bone
marrow lesions (BMLs) and synovitis on MRI are associated with
ﬂuctuations in knee pain in patients with knee OA24. These ﬁndings
were systematically reviewed within the last 2 years25. Twenty-one
studies examined the concurrent relation of MRI ﬁndings in OA to
symptoms25. Of these, just over half (13 studies) demonstrated a
statistically signiﬁcant association, deﬁned as P < 0.05, indicating
that studies to date have found inconsistent associations of struc-
tural features to symptoms. Nonetheless, in general, large bone
marrow lesions were strongly associated with knee pain, followed
by synovitis and effusion, and cartilage volume/thickness. Therewas
no consistent relation of meniscal tears to the presence of pain.
Interpretation of these relationshipsmust bemade cautiously as it is
not clear as to whether all of these associations are truly causal, or
rather are markers of the severity of other structural pathology that
may be contributing to the pain experience (Table I).
The different tissues within the joint and their respective
contribution to symptoms are discussed further below.
Hyaline articular cartilage
Articular cartilage is both aneural and avascular. As such, carti-
lage is incapable of directly generating pain, inﬂammation, stiff-
ness, or any of the symptoms that patients with OA typically
describe38, at least early on in the disease course prior to potential
neurovascular invasion that may occur in late or end-stage dis-
ease39. During cartilage degradation, substances are released that
are capable of inducing inﬂammation in the joint. Some studies
have suggested a relation between cartilage morphometry and le-
sions and the symptoms of OA40. It is important to note that this
disease of the whole joint concurrently affects other tissues that do
contain nociceptors. The studies that have demonstrated a relation
of cartilage damage to pain have traditionally investigated the role
of cartilage in predisposing to symptoms in isolation from other
tissues and as such cannot provide insight into the independent
contribution of cartilage pathology to pain. A recent studyFig. 2. Anteroposterior knee X-ray (2a) shows mild medial tibiofemoral joint space narrowi
and lateral menisci (arrows) in keeping with meniscocalcinosis. Coronal PDFS MRI (2b) con
loss of medial tibial femoral cartilage with denuded bone contrasting with mild medial tibiof
tibial and femoral bone marrow lesions (thick arrows) and moderate size tibial subspinous b
macerated and extruded. Coronal proton-density-weighted MRI (2c) shows a posterior roosuggested that areas of denuded cartilage are related to symp-
toms41. Again, the likely mechanism for symptom genesis is
through secondary mechanisms such as: (1) exposing the under-
lying subchondral bone and the inherent symptom genesis (such as
exposure of nociceptors) from this structural alteration2; vascular
congestion of subchondral bone leading to increased intraosseous
pressure3; synovitis secondary to articular cartilage damage with
activation of synovial membrane nociceptors. That is, knees
exhibiting denuded areas of cartilage are more likely to have
concomitant potentially painful tissue pathology such as synovitis/
effusion and BMLs.
Subchondral bone
Periarticular bone changes associated with OA can be segre-
gated into distinct patterns based on the anatomic location and
pathogenic mechanisms. These alterations include progressive in-
crease in subchondral plate thickness, alterations in the architec-
ture of subchondral trabecular bone, formation of new bone at the
joint margins (osteophytes), development of subchondral bone
cysts and advancement of the tidemark associated with vascular
invasion of the calciﬁed cartilage.
The osseous changes with the most supportive evidence for a
role in symptom genesis are the so-called “bone marrow lesions”
(Fig. 2). These biomechanically induced lesions in the bone marrow
reﬂecting the histologic changes of ﬁbrosis, trabecular micro-
fractures and other manifestations of bone remodelling play anng, tibial and femoral osteophytes (arrowheads) and faint calciﬁcations of both medial
ﬁrms the tibial and femoral osteophytes (arrowheads) and demonstrates an extensive
emoral joint space narrowing on X-ray. The MRI also discloses large subchondral medial
one marrow lesion at the ACL insertion (thin arrows). The medial meniscus is partially
t tear of the medial meniscus (arrow).
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OA and its structural progression27,42. More recently their relation
to pain severity29 and incident pain43 was also demonstrated. There
is conﬂicting data, albeit from smaller studies with different
methods, suggesting no relation of bone marrow lesions to
pain30,31; however the balance of data would support a strong
relation of bone marrow lesions to pain25,44.
Other bone-related causes of pain include periostitis associated
with osteophyte formation45, subchondral microfractures46, bone
attrition21 and bone angina due to decreased blood ﬂow and
elevated intraosseous pressure47, which are reﬂected on imaging as
bone marrow lesions. Given the strong relationship between bony
structural changes, symptoms and structural progression targeting
these more selectively would be a major advance in delineating
appropriate therapies.
Synovitis, effusion
Thesynovial reaction inOA includes synovialhyperplasia,ﬁbrosis,
thickening of synovial capsule, activated synoviocytes and in some
cases lymphocytic inﬁltrate (B- and T-cells as well as plasma cells)48.
Synovial causes of pain include irritation of sensory nerve endings
within the synovium from osteophytes and synovial inﬂammation
that is due, at least in part, to the release of prostaglandins, leuko-
trienes, proteinases, neuropeptides and cytokines13,49.
Synovitis and effusion is frequently present in OA and correlates
with pain and other clinical outcomes22,26,32. A semi-quantitative
measure of synovitis from the infrapatellar fat pad is associated
with pain severity and similarly change in synovitis is associated
with change in pain severity23,25,44 and pain ﬂuctuation24.
In an important caveat to this analysis a recent study compared
non-enhanced proton-density-weighted fat-suppressed (PDFS)
sequences with T1-weighted (T1w) fat-suppressed (FS) contrast-
enhanced (CE) sequences for semi-quantitative assessment of
peripatellar synovitis in OA50. These data suggested that signal al-
terations in Hoffa’s fat pad on non-enhanced images do not always
represent synovitis as seen on T1w CE images but are a rather non-
speciﬁc albeit sensitive ﬁnding (Fig. 3).
Meniscus
An intact and functional meniscus is important to the preser-
vation of joint integrity and prevention of further joint damage. In
contrast, the meniscus plays a much smaller role in symptom
genesis. There is some emerging data that incident tears and thoseFig. 3. Axial PDFS MRI (3a) shows homogeneous moderate size knee joint effusion (arrow).
not enhance after contrast administration (arrow) and true synovitis which does show enhinvolving the red zone (outer rim) of the meniscus may play a
limited role in symptom genesis through angiogenesis and associ-
ated sensory nerve growth51. However in clinical practice an un-
fortunate consequence of the frequent use of MRI in clinical
practice is the frequent detection of meniscal tears36. Degenerative
lesions, described as horizontal cleavages, ﬂap (oblique), or com-
plex tears or meniscal maceration or destruction are associated
with older age and are almost universal in persons with OA36. In
asymptomatic subjects with a mean age of 65 years, a tear was
found in 67% using MRI, whereas in patients with symptomatic
knee OA, a meniscal tear was found in 91%35. In the interests of
preserving menisci an important cautionary note: meniscal tears
are nearly universal in persons with knee OA and are unlikely to be
a cause of increased symptoms35,52. The penchant to remove
menisci is to be avoided, unless there are symptoms of locking or
extension blockade, at which point surgical treatment often be-
comes necessary53.
The role of other tissues
Periarticular muscles inﬂuence joint loading, and impairments
in muscle function have been observed in people with OA54.
Various studies have investigated the role of muscle strength on
joint integrity and some have explored the impact on physical
functioning. Sharma et al.55 conducted a 3-year longitudinal cohort
study investigating factors contributing to poor physical func-
tioning in 257 patients with knee OA. They found that in addition to
factors such as age, reduced absolute quadriceps and hamstrings
strength and poor proprioceptive acuity increased the likelihood of
poor physical functioning as measured by the time to perform ﬁve
repetitions of rising and sitting in a chair. In addition to their
exploration in observational studies there is ample evidence from
clinical trials demonstrating that muscle strengthening exercises
result in improvements in pain, physical function and quality of life
in people with knee OA56,57.
Epidemiologic insights e challenges in studying structure
pain relationships
This section will address some of the important epidemiologic
challenges and the insights that have come from imaging on
structure-symptom relationships. To date, little is known about the
natural history of structural lesions and the clinical signs and
symptoms in the development of OA. This makes studying the in-
dependent effect of each speciﬁc structural lesion on the occurrenceThe axial T1w CE FS MRI (3b) differentiates between the true joint effusion which does
ancement after contrast administration (arrowheads).
Fig. 4. The natural history of OA and the purported roles of biomarkers during the disease
process.Original attributed toVKraus (originallypresentedatOARSICongress 2009:Kraus,
VB.2009.Clinicalperspectiveon theroleofbiomarkersand thediagnosis andmonitoringof
OA. Osteoarthritis Cartilage Sept 17 (Suppl 1): S1.) can also be found in78.
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challenging.
This is especially the case as MRI technology has been more
widelyused to identify variouspathologic changes in the joint. There
is a tendency to include all structural lesions in the same statistical
model to obtain “independent” associations of various structural
lesions and risk of the outcome, such as pain, and to compare the
magnitudes of effect of each structural lesion on the outcome of
interest. Without knowing the causal pathway and chronology of
occurrence of these lesions, standard approaches of automatically
mutually adjusting for all factors can not only lead to biased effect
estimates (due to selection bias58), but the effect estimates for each
of the structural lesions are not directly comparable with one
another59,60. Thus, without improved understanding of the basic
pathogenesis of such lesions and more appropriate statistical
methods, even with improvements in the quality of image assess-
ment, such approacheswill unfortunately be unable to provide valid
insights. For example, if one is interested in assessment of the rela-
tion of meniscal extrusion and bone marrow lesions to the risk of
frequent knee pain, and assuming meniscal extrusion often occurs
before BML, any attempt to compare themagnitude of effect of each
structural lesion generated from the same regression model is
problematic. First, the effect estimate for BML reﬂects its total effect
on risk of frequent knee pain (i.e., all possible means bywhich BMLs
may exert their effects), but the effect estimate for meniscal extru-
sion represents its direct effect onpain throughpathways other than
through BMLs. These two effect estimates are not directly compa-
rable. Second, the direct effect of meniscal extrusion may be biased
owing to selection bias (i.e., collider-stratiﬁcation bias) unless
appropriate analysis methods are used61,62.
At present we do not know how much of the variance in pain is
accounted for by structural change and in addition, assessing the
causal contributions of the various pathologic features in OA to the
pain experience has been, and remains difﬁcult. One reason for this
difﬁculty is that the general approach to studying the pathologic
features in OA occurs late in the disease process when numerous
pathologic changes are already commonly present. In fact, abnor-
malities on MRI are common even in knees that are considered to
be radiographically “normal” (Kellgren and Lawrence (KL) grade 0).
For example, using data from a population-based sample of adults
aged 50 and over unselected for knee pain or knee OA, 89% of knees
that were KL ¼ 0 had at least one type of abnormality, with the
three most common ﬁndings being osteophytes (74%), cartilage
damage (69%), and bone marrow lesions (52%), and MRI-detected
abnormalities were equally highly prevalent in both those with
(91%) and without (88%) knee pain63.
Another reason for difﬁculty in discerning the relation of path-
ologic OA features to pain is because other potential confounders
are often not adequately accounted for in observational studies. As
discussed above, a number of factors, including genetics, sensiti-
zation, mood, coping, catastrophizing, and the social context,
among others, inﬂuence the pain experience. Unless such factors
are appropriately controlled for, the true magnitude of effect of
structural pathology on pain cannot be validly determined. Using a
within-person knee-matched approach to control for such
between-person differences, radiographic severity has been
demonstrated to have a strong doseeresponse relationship with
presence of pain, pain severity, and incident (new onset) pain17.
Using a different within-person knee-matched approach, Zhang
et al. demonstrated the relationship of changes in bone marrow
lesions and in synovitis/effusionwith changes in pain presence and
severity24, demonstrating that ﬂuctuation in pain can be linked to
ﬂuctuation in structural pathology. More speciﬁcally, changes in
BML and synovitis were both associated with knee pain ﬂuctuation
and pain severity24.Insights for intervention studies
Unfortunately at present there is no OA equivalent to measuring
high lipid levels, atherosclerosis, hypertension, or high glucose and
glucose tolerance, for example, as we have for cardiovascular dis-
ease and diabetes, where one can detect and treat the disease
precursors pre-emptively before the associated processes lead to
end-organ failure. In addition in OA, even if we had such a
biomarker, there are no therapies proven to reduce the risk of
progression to OA. Instead, the “watchful waiting” of steady decline
to end-stage joint disease is a major cause of disablement and loss
of quality of life10.
Recent advances in other prevalent rheumatic diseases has
resulted in diseases that were associated with inexorable decline,
be treated proactivelywith associated preservation of structure and
function. The advance of biologic therapy in rheumatoid arthritis
has seen dramatic shifts in preservation of structure and discussion
of a new classiﬁcation of disease remission. Recent evolution in
medical care for osteoporosis has seen a marked reduction in
fracture rates with their associated morbidity, with the appropriate
institution of anti-resorptive therapy. Unfortunately, we don’t have
this proactive stance available in OA, and with current structural
deﬁnitions and measurement strategies that is unlikely to change.
We need to focus on earlier disease where changes may be
reversible (Fig. 4), if we are not to continue current therapeutic
approaches that are largely palliative.
A number of obstacles exist to revising the status of OA care,
amongst these is our penchant to utilize radiography to diagnose and
studyOA64. This penchant is reinforcedby the regulatoryhurdles that
have led to promulgation of a suboptimal imaging modality in OA
studies. Utilizing radiography as ameans of deﬁning disease serves to
limit itself to a disease window that evaluates only some of the sy-
novial joint features affected by OA, and this evaluation may reﬂect
only the later stages of disease evolution. Other technologies such as
MRI may be more sensitive to early pathologic changes65. Efforts to
modify the course of the diseasemay not be successful if we focus on
late disease when the mechanical derangements overwhelm any
reparative potential66. It is akin to studying and intervening upon an
end-stage organ. If non-surgical interventions as a single therapy are
to be trialled effectively, selecting those with earlier disease, prior to
the development of marked aberrant mechanics, is a preferable so-
lution. In the recent iNOS trial67 there may have been an effect in
KL¼ 2 knees, supporting the perspective about needing to intervene
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come. The fact that the effectswere lost over the longer termsuggests
that perhaps targeting a single pathway even in milder disease may
be insufﬁcient.
The denudation of hyaline cartilage (subchondral bone exposed)
is not reversible and by the time persons develop radiographic OA,
the overwhelming majority of persons have areas of denuded
cartilage68. MRI studies provide strong evidence that ascertainment
of disease on radiographs only provides insights into late stage
disease69,70. Further we need to identify and target the tissue that
leads to the cascade of events we describe as joint failure.
Preclinical studies with varying levels of efﬁcacy suggest that a
wide array of agents including glucosamine sulphate, chondroitin
sulphate, sodium hyaluronan, doxycycline, MMP inhibitors,
bisphosphonates, calcitonin, diacerein and avocado-soybean unsa-
poniﬁables can modify disease progression71. At this point however
there is no pharmacologic agent that has been approved by regu-
latory authorities for disease modiﬁcation in OA. It may be a while
before a disease-modifying drug is available as current trial strate-
gies remain neglectful of some simple fundamentals and or
hampered by outdated regulatory requirements. Our current para-
digm of studying persons with end-stage irreversible disease needs
to change if we are to identify a stage of the disease where the
structural changes may be reversible. There are promising therapies
being developed for new OA targets for both symptoms and struc-
ture, but we need to pay heed to the lessons we have learned and
consider the obstacles to development if they are to be effective72.
Given the bulk of the evidence supporting an important relation
of synovitis/effusion and bone marrow lesions to pain in OA, these
appear, at present, to be the most promising targets for symptom
modiﬁcation. Intra-articular glucocorticoid injections, which pre-
sumably target inﬂammation related to synovitis/effusion, have
been demonstrated to be superior to placebo in the short-term, but
long-term beneﬁts have not been found73. Nonetheless, because of
the important role inﬂammatory mediators play in sensitization of
nociceptors and therefore contribute to the pain experience,
appropriate targeting of inﬂammatory cytokines (e.g., tumour ne-
crosis factor (TNF)-a, IL-1b) would be theoretically expected to
modulate symptoms.
A recent randomized trial of intravenous zoledronic acid vs
placebo demonstrated signiﬁcant bone marrow lesion area reduc-
tion as well as pain reduction at 6 months, suggesting the possi-
bility of symptom modiﬁcation by targeting of bone marrow
lesions74. Similar promising ﬁndings have also occurred for stron-
tium ranelate and calcitonin. However, since OA is a multifactorial
disease, targeting single lesions may not be successful unless other
factors are also addressed (e.g., abnormal biomechanics) and/or
intervention occurs early in the process when a particular pathway
(e.g., inﬂammation) may be the predominant driving mechanism.
The challenge lies in identifying that point in the preclinical disease
state for early intervention prior to a multitude of pathologic
pathways working in concert leading to end-stage disease.
Further, it is possible that structure modiﬁcation itself would not
necessarily have major or beneﬁcial effects on symptoms. First,
positive symptom effects may not be detectable in the time-frame
that is typically feasible for the conduct of randomized trials if
structure modiﬁcation may lead to prevention of symptoms only in
the long-term. Second, while structural pathology in the joint un-
doubtedly contributes to pain in OA, as discussed above, other fac-
tors also contribute to the pain experience. As an extreme example,
approximately 20e30% of patients report poor long-term pain
outcomes post-knee replacement, which is presumably a deﬁnitive
means of structure modiﬁcation75. Third, wemust bear in mind that
nociception plays an important protective role, and therefore com-
plete ablation of nociception should not be a therapeutic goal.Other imaging modalities may also facilitate insights into the
relation of structure to symptoms76. For example, functional MR
imaging has shown early promise in depicting the central alter-
ations consistent with the pain experience.
Research opportunities
Because the experience of pain in OA differs between in-
dividuals for the same degree of joint pathology, additional
research efforts are needed beyond solely structure modiﬁcation
for a more comprehensive approach to symptom modiﬁcation in
OA. Means of addressing poor coping skills and catastrophizing
exist through cognitive behavioural therapy, but are under-
recognized issues and such therapies are underutilized. Research
focussing on addressing these important aspects of the pain
experience would improve pain management in OA.
Insights into speciﬁc factors leading to peripheral and central
sensitization in OA would provide opportunities for therapeutic
targeting to reduce pain and potentially reduce the transition from
acute to chronic pain. For example, the relation of joint structural
alterations to peripheral sensitization remains unexamined. The
transition from acute, activity-related pain to chronic, persistent
pain is not well understood, and is the source of most of the
morbidity related to OA. If targeting inﬂammation, for example,
prevents sensitization and transition to chronic persistent pain, it
would have tremendous public health impact. It is possible that one
of the reasons for the success of TNF-a agents in rheumatoid
arthritis is not just the effects on synovial inﬂammation, but also on
sensitization as pain is so markedly improved77. Because pain
sensitization is likely an important component of the pain experi-
ence in OA, further development and testing of centrally-acting
agents that may speciﬁcally target pain mechanisms at play in OA
is warranted. Management of OA pain ideally needs to shift to a
mechanism-based approach for more optimal symptom modiﬁca-
tion. Structural modiﬁcation alone is likely to be insufﬁcient in
bringing about adequate and comprehensive pain management in
this complex disease.
As discussed previously, at present we still do not have a clear
understanding of how common are the various structural changes
and how they account for the community prevalence of knee pain.
Similarly the variance of pain explained both by independent
structural changes (e.g., BMLs vs synovitis vs effusion) as well as
their sum total remain poorly deﬁned.
Conclusion
There are many challenges in the assessment of pain aetiology
as well as methodological hurdles to overcome. Nevertheless, in
recent years many insights have been gleaned which has nar-
rowed what was previously a large discord between structural
change and the symptom experience. We would envisage that
this gap will continue to narrow as we pay greater heed to some
of the methodologic challenges highlighted in this review. With
greater understanding we can anticipate that this will lead to
therapeutic breakthroughs by virtue of targeting therapies to-
wards lesions earlier in the disease cascade and more closely
linked to the symptom experience and future structural
progression.
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